Strata Critical Medical (SRTA) director receives 35,260-share RSU grant
Rhea-AI Filing Summary
LAUCK ANDREW reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. reported that director Andrew Lauck received a grant of 35,260 Restricted Stock Units (RSUs) on 2026-07-30, which will settle in Class A common shares upon vesting. All RSUs vest on the date of the 2027 Annual Meeting of Stockholders. Following this award, Lauck's reported direct holdings are 170,902 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 35,260 shares
Net Buy
1 txn
Insider
LAUCK ANDREW
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A common stock, $0.0001 par value per share F1 | 35,260 | $0.00 | $0.00 |
Holdings After Transaction:
Class A common stock, $0.0001 par value per share — 170,902 shares (Direct)
Footnotes (1)
- F1. Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2027 Annual Meeting of Stockholders.
Key Figures
RSUs granted: 35,260 shares
Holdings after grant: 170,902 shares
RSU vesting: 100% on 2027 Annual Meeting date
3 metrics
RSUs granted
35,260 shares
Restricted Stock Units granted to director Andrew Lauck on 2026-07-30
Holdings after grant
170,902 shares
Director’s reported direct Class A common stock holdings following the award
RSU vesting
100% on 2027 Annual Meeting date
All granted RSUs vest on the date of the 2027 Annual Meeting of Stockholders
Key Terms
Restricted Stock Units ("RSUs"), vested, Annual Meeting of Stockholders, par value
4 terms
Restricted Stock Units ("RSUs") financial
"Represents a grant of Restricted Stock Units ("RSUs"), which will be settled"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vested financial
"100% of the RSUs will become vested on the date of the Issuer's 2027"
Annual Meeting of Stockholders regulatory
"100% of the RSUs will become vested on the date of the Issuer's 2027 Annual Meeting of Stockholders"
par value financial
"Class A common stock, $0.0001 par value per share"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Strata Critical Medical (SRTA) disclose in this Form 4?
Strata Critical Medical (SRTA) disclosed that director Andrew Lauck received a grant of 35,260 Restricted Stock Units (RSUs) on 2026-07-30. These RSUs will be settled in shares of Class A common stock once vested, adding to his reported direct equity position.
How many RSUs did the Strata Critical Medical (SRTA) director receive and when do they vest?
Director Andrew Lauck received 35,260 RSUs from Strata Critical Medical (SRTA). According to the footnote, 100% of these RSUs vest on the date of the company’s 2027 Annual Meeting of Stockholders, at which point they will be settled in common shares.
What are Andrew Lauck’s reported holdings in Strata Critical Medical (SRTA) after this grant?
After the RSU grant, Andrew Lauck’s reported direct holdings in Strata Critical Medical (SRTA) total 170,902 shares of Class A common stock. This figure reflects his position immediately following the award as disclosed in the non-derivative transaction table.
What type of security was granted in the Strata Critical Medical (SRTA) Form 4 filing?
The filing shows a grant of Restricted Stock Units (RSUs) that will be settled in Strata Critical Medical (SRTA) Class A common stock. The transaction is coded as a grant/award acquisition (code A) with a stated price of $0.0000 per share for the units.
Is the Strata Critical Medical (SRTA) Form 4 transaction an open-market buy or sell?
No open-market trade is reported. The Strata Critical Medical (SRTA) Form 4 describes a grant/award acquisition (transaction code A) of 35,260 RSUs at $0.0000 per share, rather than a purchase or sale executed in the market.